University of Cologne

School of Life Sciences and Technology, Indonesia Wins XVI Fujio Cup Quiz in NCRM NICHE 2021; Rajalakshmi Engineering College, India, Emerge Runners.

Retrieved on: 
화요일, 10월 19, 2021
University, Stem Cells, Biotechnology, Education, Other Health, Diabetes, Health, General Health, Research, Infectious Diseases, Science, Kyoto University, Virus, Endoplasmic reticulum stress in beta cells, School, List of life sciences, Centre for Regenerative Medicine, Technology, NASH, Regenerative medicine, Rajalakshmi Engineering College, Medical school, FCQ, B cell, Diabetes, Trust, Multimedia, Yokohama City University, GN, Research, NIMHANS, TN, Autism spectrum, University, Ensō, Global health, NHS trust, CSO, Longevity, National Centre for Science Information, Partnership, University of Toronto, NAFLD, GSZ, Cell Transplantation, Non-alcoholic fatty liver disease, NCRM, Solution, University of Cologne, Lists of diseases, EELS, COVID-19, XVI, Hiroshima University, Kasturba Medical College, Pharmaceutical industry

This press release features multimedia.

Key Points: 

SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections

Retrieved on: 
목요일, 10월 7, 2021
NASDAQ, FURI, Tablet, Patient, Medical Mycology, TIMM, IV, IC, VVC, Mucormycosis, IA, David Geffen School of Medicine at UCLA, Biotechnology, Royal College of Pathologists, Food, GLOBE, Interim analysis, University of Manchester, Refractory, UCLA, FDA, University, FACP, Fungemia, Drug of last resort, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, QIDP, Infection, University of Cologne, FAAM, Pharmaceutical industry

In addition, pre-clinical data on ibrexafungerp for the treatment of mucormycosis will be shared in an oral presentation.

Key Points: 
  • In addition, pre-clinical data on ibrexafungerp for the treatment of mucormycosis will be shared in an oral presentation.
  • There are limited oral options effective against multidrug-resistant pathogens in the hospital setting, said David Angulo, M.D., Chief Medical Officer, SCYNEXIS.
  • We hope to address this unmet need by advancing oral ibrexafungerp through these studies.
  • It is part of our ongoing commitment to patients in the hospital setting, who are battling invasive and sometimes fatal fungal infections.

Invenio Imaging receives CE Mark for NIO Laser Imaging System

Retrieved on: 
화요일, 9월 28, 2021
Invenio, University, Neurosurgery, Brain, Review, University of Cologne, Diagnosis, Histology, Surgeon, Pathology, IVDD, OR, Thermal laser stimulation, Quality, United States, CA, Technology, NIO, United, CE marking, Medicine, Medical device, Medical imaging

SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD).

Key Points: 
  • SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD).
  • This enables commercialization of this novel imaging system for intraoperative histology in the European market.
  • "The NIO Laser Imaging System represents an outstanding technique revolutionizing fast and precise intraoperative diagnosis of brain tumors," said Prof. Dr. Georg Widhalm, neurosurgeon at the University of Vienna.
  • Invenio Imaging, based in Santa Clara, CA has developed and manufactures the NIO Laser Imaging System.

Invenio Imaging receives CE Mark for NIO Laser Imaging System

Retrieved on: 
화요일, 9월 28, 2021
Invenio, University, Neurosurgery, Brain, Review, University of Cologne, Diagnosis, Histology, Surgeon, Pathology, IVDD, OR, Thermal laser stimulation, Quality, United States, CA, Technology, NIO, United, CE marking, Medicine, Medical device, Medical imaging

SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD).

Key Points: 
  • SANTA CLARA, Calif., Sept. 28, 2021 /PRNewswire/ -- Invenio Imaging announced today that it has obtained the CE Mark for the NIO Laser Imaging System according to the In Vitro Diagnostic Directive (IVDD).
  • This enables commercialization of this novel imaging system for intraoperative histology in the European market.
  • "The NIO Laser Imaging System represents an outstanding technique revolutionizing fast and precise intraoperative diagnosis of brain tumors," said Prof. Dr. Georg Widhalm, neurosurgeon at the University of Vienna.
  • Invenio Imaging, based in Santa Clara, CA has developed and manufactures the NIO Laser Imaging System.

DGAP-News: Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Retrieved on: 
월요일, 9월 20, 2021
MSD, Biotechnology, Therapy, University of Cologne, CSO, Molecular biology, CDMO, Health, CMC, Rentschler, Institute, Senior, Biochemistry, Max Planck Institute of Biochemistry, Biology, CEO, CA, Acquisition, University, Science, Technology, Non-executive director, Drug development, CFO, VP, Scripps Research, Research, Institute for Genetic Engineering and Biotechnology Sarajevo, Quality of life, Supervisory board, Industry, Max Planck Society, Independent Board for Presbyterian Foreign Missions, Management, Fine chemical

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Key Points: 
  • Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
    The issuer is solely responsible for the content of this announcement.
  • Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
    Laupheim, Germany and Milford, MA, USA, September 20, 2021 - Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer (CSO) of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: "I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.
  • Dr. Christian Schetter, Rentschler Biopharma's new CSO, added: "Rentschler Biopharma is known to deliver very high quality based on solid science.

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Retrieved on: 
월요일, 9월 20, 2021
MSD, Biotechnology, Therapy, University of Cologne, CSO, Molecular biology, CDMO, Health, CMC, Rentschler, Institute, Senior, Biochemistry, Max Planck Institute of Biochemistry, Biology, GLOBE, CEO, CA, Acquisition, University, Science, Technology, Non-executive director, Drug development, CFO, VP, Scripps Research, Research, Institute for Genetic Engineering and Biotechnology Sarajevo, Quality of life, Supervisory board, Industry, Max Planck Society, Independent Board for Presbyterian Foreign Missions, Management, Fine chemical

Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.

Key Points: 
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.
  • It is with great pleasure that I welcome him as our new CSO, commented Dr. Frank Mathias, CEO of Rentschler Biopharma.
  • Dr. Christian Schetter, Rentschler Biopharma's new CSO, added: Rentschler Biopharma is known to deliver very high quality based on solid science.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

CTG Elects James R. Helvey III to Chair of the Board of Directors

Retrieved on: 
목요일, 9월 16, 2021
Audit committee, Board, IBM, Tax, Risk management, Uncertainty, Electronic data, CTG, University of Cologne, Solution, Analysis, Contract, Polish Liquidation Committee, Wake Forest Baptist Medical Center, U.S. Securities and Exchange Commission, Result, Information technology, Â, International, Private Securities Litigation Reform Act, Trustee, Wake Forest University, NASDAQ, Growth, COVID-19, GLOBE, Financial condition report, Leadership, J.P. Morgan & Co., Security (finance), Government, J. P. Morgan, Public affairs, United States Army War College International Fellows Hall of Fame, Conversation, Achievement, University, Audit, Company, Chairperson, LLC, Risk, Retirement, Industry, Legislation, Review, EDGAR, News, Management

BUFFALO, N.Y., Sept. 16, 2021 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced the election of James Jay R. Helvey III as Chair of the CTG Board of Directors.

Key Points: 
  • BUFFALO, N.Y., Sept. 16, 2021 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of digital IT services and solutions in North America and Western Europe, today announced the election of James Jay R. Helvey III as Chair of the CTG Board of Directors.
  • He succeeds Daniel J. Sullivan, who retired today as Chair in accordance with the Companys Board retirement age guidelines.
  • We are delighted to welcome Jay as CTGs new Chair, said David H. Klein, independent director and Chair of the Nominating and Corporate Governance Committee of the CTG Board.
  • It is an honor to be elected Chair of the Board and to succeed Dan in this role, Mr. Helvey said.

Agenda Announced for the XIX International Workshop on Chronic Lymphocytic Leukemia

Retrieved on: 
화요일, 8월 10, 2021
CLL, International Workshop on Lung Health, Society for Integrative Oncology, Lymphoproliferative disorders, Patient, Physician, MD–PhD, Leukemia, Program, Medicine, University of Bonn, Chronic lymphocytic leukemia, Q&A, University, MB, Adult, Immunotherapy, Lymphatic system, Research, Hematology, Internal medicine, Doctor of Philosophy, Center, Bachelor of Medicine, Bachelor of Surgery, University of Cologne, YIM, Pharmaceutical industry

CHICAGO, Aug. 10, 2021 /PRNewswire/ -- The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), professionally organized by Bio Ascend, will occur virtually, 17-20 September 2021. The conference will feature 41 experts in the field of chronic lymphocytic leukemia (CLL), the most common type of adult leukemia. Presentations will be available on-demand starting 9 September; experts will share presentation highlights and participate in debates and Q&A sessions during live virtual sessions over the course of the conference. The keynote presentation – Advances in CLL: Is it Time to Talk Cure – will be delivered by Professor Michael Hallek, MD, PhD, on 20 September.

Key Points: 
  • The virtual conference explores the latest research and innovations in treating CLL, in both live and on-demand formats
    CHICAGO, Aug. 10, 2021 /PRNewswire/ --The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), professionally organized by Bio Ascend, will occur virtually, 17-20 September 2021.The conference will feature 41 experts in the field of chronic lymphocytic leukemia (CLL), the most common type of adult leukemia.
  • The keynote presentation Advances in CLL: Is it Time to Talk Cure will be delivered by Professor Michael Hallek, MD, PhD, on 20 September.
  • This biennial international conference will focus on these main themes: pathogenesis of CLL, approach considerations and treatment options, and rationally designed therapies on the horizon.
  • The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) is a biennial meeting focused solely on advancing the understanding and treatment of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders.

Agenda Announced for the XIX International Workshop on Chronic Lymphocytic Leukemia

Retrieved on: 
화요일, 8월 10, 2021
CLL, International Workshop on Lung Health, Society for Integrative Oncology, Lymphoproliferative disorders, Patient, Physician, MD–PhD, Leukemia, Program, Medicine, University of Bonn, Chronic lymphocytic leukemia, Q&A, University, MB, Adult, Immunotherapy, Lymphatic system, Research, Hematology, Internal medicine, Doctor of Philosophy, Center, Bachelor of Medicine, Bachelor of Surgery, University of Cologne, YIM, Pharmaceutical industry

CHICAGO, Aug. 10, 2021 /PRNewswire/ --The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), professionally organized by Bio Ascend, will occur virtually, 17-20 September 2021.The conference will feature 41 experts in the field of chronic lymphocytic leukemia (CLL), the most common type of adult leukemia.

Key Points: 
  • CHICAGO, Aug. 10, 2021 /PRNewswire/ --The International Workshop on Chronic Lymphocytic Leukemia (iwCLL), professionally organized by Bio Ascend, will occur virtually, 17-20 September 2021.The conference will feature 41 experts in the field of chronic lymphocytic leukemia (CLL), the most common type of adult leukemia.
  • The keynote presentation Advances in CLL: Is it Time to Talk Cure will be delivered by Professor Michael Hallek, MD, PhD, on 20 September.
  • This biennial international conference will focus on these main themes: pathogenesis of CLL, approach considerations and treatment options, and rationally designed therapies on the horizon.
  • The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) is a biennial meeting focused solely on advancing the understanding and treatment of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders.

TCG Digital Appoints Mikael Hagstroem and Wolf Lichtenstein to the Leadership Team

Retrieved on: 
월요일, 7월 26, 2021
Albums, TCG

I am honoured to welcome both Mikael and Wolf to the TCG family and excited at the prospect of what we can achieve together."

Key Points: 
  • I am honoured to welcome both Mikael and Wolf to the TCG family and excited at the prospect of what we can achieve together."
  • Mikaelbrings TCG Digital nearly 30 years of experience as a leader in digital transformation.
  • TCG Digital's CEO, Debdas Sen commented, "We are delighted to welcome Mikael Hagstroem and Wolf Lichtenstein to TCG Digital.
  • TCG Digital is the flagship data science, digital transformation, and IT consulting company of The Chatterjee Group (TCG), a multi-billion dollar portfolio of corporations headquartered in New York.